Vertex Pharmaceuticals (VRTX) Change in Acquisitions & Divestments (2009 - 2026)

Vertex Pharmaceuticals' Change in Acquisitions & Divestments history runs 18 years deep, the most recent figure standing at $2.2 billion for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 34.9% year-over-year to $2.2 billion in Q1 2026; TTM through Mar 2026 was $587.5 million, a 89.11% decrease from a year earlier, with the FY2025 full-year figure at $16.0 million, down 99.64% from the prior year.
• Change in Acquisitions & Divestments rose to $2.2 billion in Q1 2026 per VRTX's latest filing, from -$4.8 billion in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $2.2 billion in Q1 2026 and bottomed at -$4.8 billion in Q4 2025.
• The 5-year median for Change in Acquisitions & Divestments is $525.9 million (2023), against an average of $497.0 million.
• Across the five-year window, Change in Acquisitions & Divestments soared 2522.17% in 2024 and slumped 428.01% in 2025, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $484.1 million in 2022, then sank by 54.95% to $218.1 million in 2023, then surged by 569.51% to $1.5 billion in 2024, then slumped by 428.01% to -$4.8 billion in 2025, then soared by 146.12% to $2.2 billion in 2026.
• Per Business Quant, the three latest VRTX Change in Acquisitions & Divestments figures stand at $2.2 billion (Q1 2026), -$4.8 billion (Q4 2025), and $1.3 billion (Q3 2025).